Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.O)

REGN.O on Nasdaq

398.52USD
16 Oct 2018
Change (% chg)

$20.97 (+5.55%)
Prev Close
$377.55
Open
$381.31
Day's High
$399.40
Day's Low
$380.78
Volume
684,490
Avg. Vol
719,126
52-wk High
$453.55
52-wk Low
$281.89

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $41,837.05
Shares Outstanding(Mil.): 106.14
Dividend: --
Yield (%): --

Financials

  REGN.O Industry Sector
P/E (TTM): 23.73 119.85 32.14
EPS (TTM): 16.61 -- --
ROI: 24.43 1.96 12.83
ROE: 30.18 1.12 14.95

Sanofi, Regeneron say late-stage Dupixent trials show positive results

PARIS, Oct 16 Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues.

1:20am EDT

SCOTUS denies Regeneron request for review of inequitable conduct finding

Regeneron Pharmaceuticals Inc on Monday hit a dead end in its long-running bid to undo a ruling that a patent it had sought to enforce against rival Merus NV was unenforceable because it had been obtained through deception.

Oct 01 2018

Sanofi, Regeneron skin cancer drug gets FDA nod

Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

Sep 28 2018

UPDATE 1-Sanofi, Regeneron skin cancer drug gets FDA nod

Sept 28 Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

Sep 28 2018

Sanofi, Regeneron skin cancer drug gets FDA nod

Sept 28 Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

Sep 28 2018

Sanofi pledges to keep up its restructuring efforts

(This version of the Sept. 14th story has been refiled to add dropped words in fifth paragraph)

Sep 18 2018

REFILE-UPDATE 1-Sanofi pledges to keep up its restructuring efforts

PARIS, Sept 14 Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well.

Sep 18 2018

Factbox: Challenges facing German pharmaceutical company Bayer

FRANKFURT Bayer is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November, a person familiar with the company told Reuters.

Sep 04 2018

Regeneron's anti-blindness drug approved for less frequent treatments

Aug 17 Regeneron said on Friday it had won U.S. Food and Drug Administration approval for less-frequent applications of its Eylea anti-blindness treatment, which may come under pressure from a rival product made by Novatis

Aug 17 2018

Regeneron to invest $100 million in bluebird, jointly develop cancer therapies

Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer.

Aug 06 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF84.08 +1.62
Pfizer Inc. (PFE.N) $43.93 +0.81
Bayer AG (BAYGn.DE) €78.28 +0.21
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.41 --
Merck & Co., Inc. (MRK.N) $71.22 +1.76
Amgen, Inc. (AMGN.OQ) $202.34 +6.75
Roche Holding Ltd. (ROG.S) CHF240.55 +5.30
Roche Holding Ltd. (RO.S) CHF241.00 +4.40
Eli Lilly And Co (LLY.N) $111.03 +0.41

Earnings vs. Estimates